Exelixis Inc (EXEL) — Analysis Summary
Exelixis Inc (EXEL) has a market cap of $12.69B with year-over-year revenue growth of +7.0%. Net margin stands at 33.7%. The stock trades at a P/E ratio of 15.2.
Key Takeaways
- Revenue changed +7.0% year-over-year
- Net margin of 33.7%
- P/E ratio of 15.2
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, EXEL posted revenue growth of +7.0% and trades at a P/E of 15.2.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.